...
首页> 外文期刊>Europace: European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology >Association between frequent cardiac resynchronization therapy optimization and long-term clinical response: a post hoc analysis of the Clinical Evaluation on Advanced Resynchronization (CLEAR) pilot study.
【24h】

Association between frequent cardiac resynchronization therapy optimization and long-term clinical response: a post hoc analysis of the Clinical Evaluation on Advanced Resynchronization (CLEAR) pilot study.

机译:频繁的心脏再同步治疗优化与长期临床反应之间的关联:高级再同步临床评估(CLEAR)初步研究的事后分析。

获取原文
获取原文并翻译 | 示例
           

摘要

The long-term clinical value of the optimization of atrioventricular (AVD) and interventricular (VVD) delays in cardiac resynchronization therapy (CRT) remains controversial. We studied retrospectively the association between the frequency of AVD and VVD optimization and 1-year clinical outcomes in the 199 CRT patients who completed the Clinical Evaluation on Advanced Resynchronization study.From the 199 patients assigned to CRT-pacemaker (CRT-P) (New York Heart Association, NYHA, class III/IV, left ventricular ejection fraction <35%), two groups were retrospectively composed a posteriori on the basis of the frequency of their AVD and VVD optimization: Group 1 (n = 66) was composed of patients 'systematically' optimized at implant, at 3 and 6 months; Group 2 (n = 133) was composed of all other patients optimized 'non-systematically' (less than three times) during the 1 year study. The primary endpoint was a composite of all-cause mortality, heart failure-related hospitalization, NYHA functional class, and Quality of Life score, at 1 year. Systematic CRT optimization was associated with a higher percentage of improved patients based on the composite endpoint (85% in Group 1 vs. 61% in Group 2, P < 0.001), with fewer deaths (3% in Group 1 vs. 14% in Group 2, P = 0.014) and fewer hospitalizations (8% in Group 1 vs. 23% in Group 2, P = 0.007), at 1 year.These results further suggest that AVD and VVD frequent optimization (at implant, at 3 and 6 months) is associated with improved long-term clinical response in CRT-P patients.
机译:在心脏再同步治疗(CRT)中优化房室(AVD)和心室间(VVD)延迟的长期临床价值仍存在争议。我们回顾性研究了199位完成了高级再同步化临床评估研究的CRT患者中AVD和VVD优化频率与1年临床结局之间的关系。来自199位被分配给CRT-pacemaker(CRT-P)的患者(新约克心脏协会(NYHA),III / IV级,左心室射血分数<35%),根据AVD和VVD优化的频率回顾性地组成两组:第1组(n = 66)患者在植入后3个月和6个月“系统地”优化;第2组(n = 133)由在1年研究中“非系统性”优化的所有其他患者(少于3次)组成。主要终点是1年时所有原因的死亡率,与心力衰竭相关的住院,NYHA功能分类和生活质量评分的综合。基于复合终点,系统性CRT优化与改善患者比例更高相关(第1组为85%,第2组为61%,P <0.001),死亡人数较少(第1组为3%,而第3组为14%)。第2组,P = 0.014),住院1年的住院率较低(第1组为8%,第2组为23%,P = 0.007),这些结果进一步表明AVD和VVD的优化频率较高(植入时,第3和6个月)与CRT-P患者的长期临床反应改善有关。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号